Join us for a panel discussion exploring the latest breakthroughs in precision oncology and their transformative impact on cancer treatment. Learn about cutting-edge research, emerging technologies, and collaborative approaches that are accelerating progress toward more personalized care across diverse tumor types. Whether your interest is personal or professional, this session offers a compelling look at the future of oncology.

Note: Register with the button above. Upon registration, you will receive a link to a security info form from J&J (JLABS) that must be completed prior to entering the event.

Each ticket includes light bites and non-alcoholic beverages. Walk-ins will not be accepted. 

Program

6:00 p.m. – 6:30 p.m.  Check in and networking
6:30 p.m. – 7:30 p.m.  Panel discussion
7:30 p.m. – 8:00 p.m.  Q&A and networking
 

Speaker Bios

Candy Bermingham, PhD, Vice President and Head of Clinical Science at Arcus Biosciences

Candy is the Vice President and Head of Clinical Science at Arcus Biosciences, where she is managing the development of 7 oncology assets, from Phase 1 to Phase 3 registrational studies. She has over 20 years of experience within the biotech and pharmaceutical industry. She has been responsible for numerous Investigational New Drug (IND) submissions for immuno-oncology and oncology targeted therapies and holds nine patents. Prior to Arcus Biosciences, Candy held multiple clinical development positions within the field of oncology, serving as Vice President of Clinical Science at Tallac Therapeutics, Senior Director of Clinical Science at Aduro Biotech and Exelixis, and Director, Study Clinician at Pfizer. Early in her career, she led the target validation efforts for oncology target discovery research at Celera Genomics. Candy holds a PhD in biochemistry and applied molecular biology from the University of Manchester, UK, and completed her postdoctoral training in hematopoietic stem cell biology at the Yale School of Medicine.

Kawa Chiu, Chief Technical Officer at Abdera Therapeutics

Kawa is Chief Technical Officer at Abdera Therapeutics, a biopharmaceutical company advancing precision radiopharmaceuticals through antibody engineering to treat cancer. Under her leadership, Abdera developed ABD-147 and ABD-320, Actinium-225 therapeutics paired with Indium-111 imaging agents targeting DLL3- and 5T4-expressing tumors. ABD-147 received FDA Fast Track and Orphan Drug designations in 2024 and is currently in clinical trials. Previously, Kawa was an early executive at Lyell Immunopharma, where she built CMC and patient operations enabling three INDs for cell therapies. At Genentech/Roche, she held global leadership roles including Head of Oceanside Drug Substance Manufacturing, Global Head of Technical Operations Strategy, and Global Head of Supply Planning. She began her career with a decade at Merck. Kawa holds an MPH from UC Berkeley, an MBA from NYU, and an MSc in engineering from the University of Pennsylvania.

Anne-Renee Hartman, MD, Co-founder and Chief Medical Officer of Adela

Dr. Hartman is a visionary leader in precision medicine with over 18 years of experience commercializing innovative cancer detection and diagnostic technologies. As Co-founder and Chief Medical Officer of Adela, she has developed MRD and response monitoring applications, including Adela's Guidepoint MRD test for head and neck cancer. Previously, she served as VP of Clinical Development at GRAIL, where she led the clinical development of the Galleri Multi-Cancer Early Detection test, and as SVP of Clinical Development at Myriad Genetics, where she led the clinical development of multiple products, including MyRisk (Myriad Hereditary Cancer Test) and MyChoice CDx (Myriad HRD Companion Diagnostic Test). Dr. Hartman earned her MD from the University of Michigan, completed internal medicine training at the University of Chicago, and received fellowship training at Stanford University Medical Center. She also served as Assistant Professor of Medicine at Dana Farber Cancer Institute and Harvard Medical School.

Jodi Lipof, MD, Assistant Professor, Hematology & Oncology at The University of California, San Francisco

Dr. Jodi Lipof is a hematologist and medical oncologist with clinical and research expertise in plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma, multiple myeloma, and systemic light-chain (AL) amyloidosis. Her clinical practice encompasses the management of patients undergoing autologous stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy for plasma cell malignancies. Dr. Lipof’s research focuses on the design and conduct of clinical trials investigating novel therapeutics for plasma cell disorders. She has a particular interest in optimizing therapeutic sequencing and treatment strategies in multiple myeloma to improve clinical outcomes in the context of rapidly evolving therapeutic options. In addition, her research examines post–CAR T-cell therapy toxicities, including persistent cytopenias, secondary malignancies, and delayed neurotoxicities, with the aim of improving long-term safety and survivorship in this patient population.
 

Manal Mehibel, PhD, Oncology Precision Medicine Lead at AbbVie

Manal is a Precision Medicine Lead and Associate Director at AbbVie, where she drives biomarker strategies to accelerate the development of targeted oncology therapeutics, with a focus on antibody-drug conjugates. With deep expertise cultivated through her experience from both the pharmaceutical industry and academia, Manal is committed to advancing precision medicine to help cancer patients, moving beyond a one-size-fits-all approach. She holds a PhD in experimental oncology from the University of Manchester (UK), a postdoctoral fellowship at the Stanford School of Medicine, and a pharmacy degree from Nottingham University (UK). 

Guneet Walia, PhD, Senior Director, Data Science & Digital Health at Johnson and Johnson, Moderator

Guneet leads the AI-driven diagnostics portfolio for J&J, focusing on innovative precision diagnostics tools such as computational pathology, radiomics, etc. She brings more than 14 years of experience in oncology precision medicine, spanning drug and diagnostic development, as well as multi-modal RWE. Prior to her current role at J&J, she has held senior roles at Roche-Genentech, GRAIL, the Go2 Foundation for Lung Cancer, and the Prostate Cancer Foundation, where she has built research portfolios, enduring strategic partnerships, and innovative precision medicine tools in multi-cancer early detection (MCED), minimal residual disease (MRD), prospective, multi-modal RWD-based clinical research platforms, etc. Guneet holds a master's and PhD in molecular biophysics from the Indian Institute of Science (IISc) and is passionate about keeping the patient at the center of everything we do in healthcare. 

Pricing Information

• Members: $35
• Student Members: $20
• Non-members*: $65
• Student Non-members: $40

*Interested in joining Women In Bio? Click here to learn more about WIB membership and gain access to our video library, mentorship opportunities, and more. 

Please read WIB's Code of Conduct and Refund Policy.

Note: A confirmation email will be sent after registration has been completed. 

Maximum Capacity

100

Parking Information

Free parking is available at the venue. 

Accessibility Accommodations

This location is fully accessible with elevators available to the 3rd Floor.